Summary: Merck & Co., Inc.

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Merck & Co., Inc.

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 12.45 for the current year.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Merck & Co., Inc.

  • The company's enterprise value to sales, at 3.8 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings Chart: Merck & Co., Inc.

Source: Surperformance

ESG chart: Merck & Co., Inc.

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
221B
791B
387B
369B
337B
255B
223B
210B
158B
146B
Average 309.6B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
A

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health

Valuation

P/E ratio
EV/REVENUE
EV/EBITDA
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Ratings Merck & Co., Inc.